Canakinumab: New treatment choice for systemic juvenile idiopathic arthritis
dc.contributor.author | Sozeri B. | |
dc.contributor.author | Sevgi S. | |
dc.contributor.author | Kasapcopur O. | |
dc.date.accessioned | 2019-10-26T21:26:31Z | |
dc.date.available | 2019-10-26T21:26:31Z | |
dc.date.issued | 2015 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and systemic juvenile idiopathic arthritis (sJIA) accounts for 6-15% of the patients. It was found that there was spontaneous expression of IL-1ß in patients with sJIA. Canakinumab (ACZ885, Canakinumab) is a human anti-IL-1ß monoclonal antibody. Its mode of action is based on the neutralization of IL-1ß signaling which may result in the suppression of inflammation process in patients with disorders of autoinflammatory origin including sJIA. In addition to its use in the treatment of CAPS (cryopyrin-associated periodic syndromes) and acute gouty arthritis flares in many countries, the drug provides significant advantages over existing competitive therapies, including monthly SC administration and favorable safety profile. © 2015 Future Medicine Ltd. | en_US |
dc.identifier.doi | 10.2217/ijr.14.53 | |
dc.identifier.endpage | 19 | en_US |
dc.identifier.issn | 1758-4272 | |
dc.identifier.issn | 1758-4272 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.scopusquality | N/A | en_US |
dc.identifier.startpage | 13 | en_US |
dc.identifier.uri | https://doi.org/10.2217/ijr.14.53 | |
dc.identifier.uri | https://hdl.handle.net/11454/17351 | |
dc.identifier.volume | 10 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.language.iso | en | en_US |
dc.publisher | Future Medicine Ltd. | en_US |
dc.relation.ispartof | International Journal of Clinical Rheumatology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | anti-interleukin-1 | en_US |
dc.subject | canakinumab | en_US |
dc.subject | systemic juvenile idiopathic arthritis | en_US |
dc.title | Canakinumab: New treatment choice for systemic juvenile idiopathic arthritis | en_US |
dc.type | Article | en_US |